Botulinum toxin has an increased effect when targeted toward the muscle's endplate zone: A high-density surface EMG guided study

Clinical Neurophysiology

Volumn 122, Issue 8, 2011, Pages 1611-1616

  Lapatki, B G ^a,b   Van Dijk, J P ^c   Van de Warrenburg, B P C ^c   Zwarts, M J ^c  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c RADBOUD UNIVERSITY   (Netherlands)

Author keywords

Botulinum toxin; Dystonia; EMG; Endplate

Indexed keywords

BOTULINUM TOXIN A;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ELECTROMYOGRAM; EXTENSOR DIGITORUM LONGUS MUSCLE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MUSCLE ACTION POTENTIAL; NERVE ENDING; NEUROIMAGING; NORMAL HUMAN; PRIORITY JOURNAL; SURFACE PROPERTY;

ADULT; BOTULINUM TOXINS, TYPE A; ELECTROMYOGRAPHY; EVOKED POTENTIALS, MOTOR; FEMALE; FUNCTIONAL LATERALITY; HUMANS; MALE; MIDDLE AGED; MOTOR ENDPLATE; MUSCLE, SKELETAL; NEUROMUSCULAR AGENTS; TIME FACTORS; YOUNG ADULT;

EID: 79960250935     PISSN: 13882457     EISSN: 18728952     Source Type: Journal    
DOI: 10.1016/j.clinph.2010.11.018     Document Type: Article

References (36)

1. Bakheit A.M. The possible adverse effects of intramuscular botulinum toxin injections and their management. Curr Drug Saf 2006, 1:271-279.
2. Borodic G.E., Cozzolino D., Ferrante R., Wiegner A.W., Young R.R. Innervation zone of orbicularis oculi muscle and implications for botulinum A toxin therapy. Ophthal Plast Reconstr Surg 1991, 7:54-60.
3. Borodic G.E., Ferrante R., Pearce L.B., Smith K. Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections. Mov Disord 1994, 9:31-39.
4. Borodic G.E., Joseph M., Fay L., Cozzolino D., Ferrante R.J. Botulinum A toxin for the treatment of spasmodic torticollis: dysphagia and regional toxin spread. Head Neck 1990, 12:392-399.
5. Brans J.W., de Boer I.P., Aramideh M., Ongerboer de Visser B.W., Speelman J.D. Botulinum toxin in cervical dystonia: low dosage with electromyographic guidance. J Neurol 1995, 242:529-534.
6. Breidenbach M.A., Brunger A.T. New insights into clostridial neurotoxin-SNARE interactions. Trends Mol Med 2005, 11:377-381.
7. Castroflorio T., Farina D., Bottin A., Debernardi C., Bracco P., Merletti R., et al. Non-invasive assessment of motor unit anatomy in jaw-elevator muscles. J Oral Rehabil 2005, 32:708-713.
8. Childers M.K. The importance of electromyographic guidance and electrical stimulation for injection of botulinum toxin. Phys Med Rehabil Clin N Am 2003, 14:781-792.
9. Childers M.K. Targeting the neuromuscular junction in skeletal muscles. Am J Phys Med Rehabil 2004, 83:S38-S44.
10. Childers M.K., Kornegay J.N., Aoki R., Otaviani L., Bogan D.J., Petroski G. Evaluating motor end-plate-targeted injections of botulinum toxin type A in a canine model. Muscle Nerve 1998, 21:653-655.
11. Collins A., Jankovic J. Botulinum toxin injection for congenital muscular torticollis presenting in children and adults. Neurology 2006, 67:1083-1085.
12. Dressler D., Benecke R. Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil 2007, 29:1761-1768.
13. Dressler D., Hallett M. Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc. Eur J Neurol 2006, 13(Suppl. 1):11-15.
14. Eleopra R., Tugnoli V., Caniatti L., De Grandis D. Botulinum toxin treatment in the facial muscles of humans: evidence of an action in untreated near muscles by peripheral local diffusion. Neurology 1996, 46:1158-1160.
15. Falla D., Dall'Alba P., Rainoldi A., Merletti R., Jull G. Location of innervation zones of sternocleidomastoid and scalene muscles - a basis for clinical and research electromyography applications. Clin Neurophysiol 2002, 113:57-63.
16. Farina D., Merletti R., Indino B., Nazzaro M., Pozzo M. Surface EMG crosstalk between knee extensor muscles: experimental and model results. Muscle Nerve 2002, 26:681-695.
17. Gracies J.M., Lugassy M., Weisz D.J., Vecchio M., Flanagan S., Simpson D.M. Botulinum toxin dilution and endplate targeting in spasticity: a double-blind controlled study. Arch Phys Med Rehabil 2009, 90:9-16.
18. Greene P., Fahn S., Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994, 9:213-217.
19. Happak W., Liu J., Burggasser G., Flowers A., Gruber H., Freilinger G. Human facial muscles: dimensions, motor endplate distribution, and presence of muscle fibers with multiple motor endplates. Anat Rec 1997, 249:276-284.
20. Jankovic J., Schwartz K. Botulinum toxin injections for cervical dystonia. Neurology 1990, 40:277-280.
21. Jankovic J., Vuong K.D., Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 2003, 60:1186-1188.
22. Lapatki B.G., Oostenveld R., Van Dijk J.P., Jonas I.E., Zwarts M.J., Stegeman D.F. Topographical characteristics of motor units of the lower facial musculature revealed by means of high-density surface EMG. J Neurophysiol 2006, 95:342-354.
23. Lapatki B.G., Van Dijk J.P., Jonas I.E., Zwarts M.J., Stegeman D.F. A thin, flexible multielectrode grid for high-density surface EMG. J Appl Physiol 2004, 96:327-336.
24. Ludlow C.L., Naunton R.F., Sedory S.E., Schulz G.M., Hallett M. Effects of botulinum toxin injections on speech in adductor spasmodic dysphonia. Neurology 1988, 38:1220-1225.
25. Masuda T., Miyano H., Sadoyama T. The propagation of motor unit action potential and the location of neuromuscular junction investigated by surface electrode arrays. Electroencephalogr Clin Neurophysiol 1983, 55:594-600.
26. Masuda T., Sadoyama T. Topographical map of innervation zones within single motor units measured with a grid surface electrode. IEEE Trans Biomed Eng 1988, 35:623-628.
27. Naumann M., So Y., Argoff C.E., Childers M.K., Dykstra D.D., Gronseth G.S., et al. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008, 70:1707-1714.
28. Sampaio C., Costa J., Ferreira J.J. Clinical comparability of marketed formulations of botulinum toxin. Mov Disord 2004, 19(Suppl. 8):S129-S136.
29. Shaari C.M., Sanders I. Quantifying how location and dose of botulinum toxin injections affect muscle paralysis. Muscle Nerve 1993, 16:964-969.
30. Simpson D.M., Blitzer A., Brashear A., Comella C., Dubinsky R., Hallett M., et al. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008, 70:1699-1706.
31. Simpson D.M., Gracies J.M., Graham H.K., Miyasaki J.M., Naumann M., Russman B., et al. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008, 70:1691-1698.
32. Sloop R.R., Escutin R.O., Matus J.A., Cole B.A., Peterson G.W. Dose-response curve of human extensor digitorum brevis muscle function to intramuscularly injected botulinum toxin type A. Neurology 1996, 46:1382-1386.
33. Stegeman D.F., Houtman C.J., Lapatki B.G., Zwarts M.J. Multichannel surface EMG. Handbook of clinical neurophysiology 2004, Elsevier, Amsterdam. E. Stalberg (Ed.).
34. Truong D.D., Jost W.H. Botulinum toxin: clinical use. Parkinsonism Relat Disord 2006, 12:331-355.
35. van Dijk J.P., Lowery M.M., Lapatki B.G., Stegeman D.F. Evidence of potential averaging over the finite surface of a bioelectric surface electrode. Ann Biomed Eng 2009, 37:1141-1151.
36. Warfel J. The extremeties - muscles and motor points 1985, Lea & Febiger, Philadelphia.